Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab)
Monday, January 29, 2024Celltrion USA today announced the submission of Biologics License Application BLA to the US Food and Drug Administration FDA for CTP a biosimilar candidate of the reference product ACTEMRA
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Friday, January 26, 2024LAVA Therapeutics NV today announced that it has entered into a clinical trial collaboration and supply agreement with Merck Co Inc Rahway NJ USA to evaluate its antiPD therapy KEYTRUDA
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases
Thursday, January 25, 2024Kyowa Kirin Co Ltd a Japanbased global specialty pharmaceutical company discovering and developing novel medicines utilizing the latest biotechnology and Orchard Therapeutics plc
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
Thursday, January 25, 2024Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines announces an expanded commitment to developing tailored cancer vaccines
BlueRock Therapeutics licenses OpCT-001 for Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
Wednesday, January 24, 2024BlueRock Therapeutics LP a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG announced today that it has exercised its option to exclusively license OpCT an induced pluripotent stem
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
Wednesday, January 24, 2024Cybin Inc a clinicalstage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration psychedelic treatment options today announced that the US Food and Drug Administration
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Tuesday, January 23, 2024ProMIS Neurosciences Inc a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases today announced the selection of a lead vaccine candidate
AIM ImmunoTech Enrolls First Subject in Phase 1b/2 Study of Ampligen® and AstraZeneca’s Imfinzi® for Late-Stage Pancreatic Cancer
Tuesday, January 23, 2024AIM ImmunoTech Inc today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase b clinical trial combining AIMs Ampligen with AstraZenecas antiPDL immune
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
Monday, January 22, 2024BioNTech SE and Duality Biologics today announced that the first patient with metastatic breast cancer has been treated in a pivotal Phase trial evaluating the efficacy and safety of the nextgeneration antibodydrug conjugate
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Saturday, January 20, 2024Processa Pharmaceuticals Inc a clinicalstage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer
